Heartflow (NASDAQ:HTFL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Heartflow (NASDAQ:HTFL) from a hold rating to a buy rating in a research report report published on Sunday,Wall Street Zen reports.

A number of other research analysts also recently commented on the stock. UBS Group began coverage on shares of Heartflow in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 target price on the stock. Stifel Nicolaus boosted their price target on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a research note on Friday, August 14th. Morgan Stanley raised their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Finally, Canaccord Genuity Group lifted their target price on Heartflow from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and an average price target of $48.62.

Heartflow Stock Performance

Shares of HTFL stock opened at $57.82 on Friday. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $59.90. The company has a 50 day moving average price of $50.00 and a 200 day moving average price of $33.76.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, equities analysts predict that Heartflow will post -0.75 earnings per share for the current year.

Insider Transactions at Heartflow

In other news, CEO John Farquhar sold 38,900 shares of Heartflow stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $49.57, for a total transaction of $1,928,273.00. Following the completion of the sale, the chief executive officer directly owned 283,014 shares in the company, valued at approximately $14,029,003.98. This trade represents a 12.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 23,933 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total value of $1,316,554.33. Following the completion of the sale, the insider directly owned 73,453 shares in the company, valued at $4,040,649.53. This trade represents a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 328,038 shares of company stock valued at $15,490,354. Corporate insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Heartflow

Several hedge funds have recently bought and sold shares of the stock. XXEC Inc. acquired a new position in shares of Heartflow in the second quarter valued at approximately $2,524,764,000. BlackRock Inc. acquired a new stake in Heartflow during the second quarter worth approximately $152,502,000. Bamco Inc. NY acquired a new stake in Heartflow during the second quarter worth approximately $94,625,000. Jupiter Topco LLC purchased a new stake in Heartflow in the 2nd quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC grew its stake in Heartflow by 152.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after acquiring an additional 1,315,416 shares during the period.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries and provide noninvasive assessments of blood flow and disease.

The company’s products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.